Protocole Thérapeutique : Cancer du Sein

Objectives

The protocol provides an evidence-based framework for breast-cancer prevention, diagnosis, treatment and follow-up, intended to support clinical decision-making for patients covered by long-term or other eligible conditions while preserving clinicians’ responsibility to tailor care to individual circumstances.[1]It responds to breast cancer as a major cause of morbidity and mortality among women, including reported incidence rates of 35.04 per 100,000 women in Greater Casablanca in 2004 and 36 per 100,000 in Rabat in 2005.[2]

• Reduce mortality through risk reduction, early detection, timely diagnostic confirmation and appropriate treatment.[3][4]
• Prevent disease by addressing modifiable risks, including tobacco use, carcinogenic products and inappropriate oestrogen or progestogen use, while recognising bilateral mastectomy as a preventive option for women with BRCA1 or BRCA2 mutations.[3]
• Screen women from age 45 using two-yearly mammography with craniocaudal and external-oblique views, with earlier screening for women with BRCA1 or BRCA2 mutations and potential continuation beyond age 70.[4]
• Confirm suspected malignancy histologically before surgical or systemic treatment, using image-guided biopsy, stereotactic localisation and excision, or surgical biopsy when image-guided sampling is not feasible.[5][6]
• Standardise pathological diagnosis, prognostic assessment and staging through World Health Organization histological classification, International Classification of Diseases coding where applicable, standard pathology reporting and the 2003 sixth-edition American Joint Committee on Cancer TNM classification.[7][8]
• Deliver multidisciplinary, stage- and biology-adapted care spanning breast and axillary surgery, reconstruction, radiotherapy, chemotherapy, endocrine therapy and targeted therapy.[9][10][11][12]
• Support patients through management of treatment complications, rehabilitation, lymphoedema care, psychosocial and social support, therapeutic education, recurrence detection and occupational reintegration.[13][14][15]

Clinical decisions are to be based on systematically reviewed evidence and graded recommendations: grade A denotes established scientific evidence, grade B presumed evidence and grade C low-level evidence, while strong professional consensus may be used when evidence is insufficient.[16]The protocol covers presentation, prevention, screening, diagnostic assessment, primary and metastatic treatment, relapse management, surveillance, patient information and clinical decision algorithms.[17][1][18]

Implementation

Implementation combines nationally governed protocol development with multidisciplinary clinical delivery. The Ministry of Health, National Health Insurance Agency, Moroccan Society of Medical Sciences and National Council of the Medical Order are partners in the protocol framework; the Moroccan Society of Medical Sciences coordinates multidisciplinary working groups and validates protocols through its coordination committee.[19]Approved protocols are reviewed by the Society’s Coordination Committee, the National Health Insurance Agency’s Medical Technical Committee and the Minister of Health, then disseminated to health professionals, institutions and other health-sector stakeholders.[20]

• Develop protocols through a designated scientific society and multidisciplinary group comprising a coordinator, literature-synthesis contributors and a rapporteur, supported by declarations of honour or interests from members.[19][16]
• Search MEDLINE and the Cochrane Library, prioritising consensus material, clinical recommendations, trials, meta-analyses, decision analyses and systematic reviews in French or English, supplemented by manual searching, reference tracing and group input.[16]
• Subject draft protocols to external review for content, format, readability and applicability, and verify adherence to the required methodology, terms of reference and standard template.[20]
• Deliver screening through mammography interpreted independently by two radiologists at different times, and assess symptomatic women through history-taking, examination, bilateral mammography and ultrasound where needed.[3][4]
• Use magnetic resonance imaging selectively for unresolved diagnostic findings, occult primary disease, assessment after neoadjuvant treatment, suspected recurrence and known genetic mutations.[21]
• Coordinate surgery, oncology and radiotherapy, including multidisciplinary consultation for incomplete axillary dissection, progression or absent response to neoadjuvant treatment, and selection of subsequent treatment.[9][22]
• Provide radiotherapy with defined target volumes, computed-tomography-based dosimetry where available, verification imaging and mandatory weekly medical review during treatment.[10]
• Tailor systemic treatment to disease setting, hormone-receptor status, human epidermal growth factor receptor 2 status, prior therapy, comorbidities, disease burden and patient preferences.[11][23][24]

Quality assurance is embedded in diagnostic reporting, evidence review and follow-up. Imaging reports should record Breast Imaging Reporting and Data System classification and diagnostic hypotheses, while pathology reports should document tumour characteristics, margins, nodal findings and predictive markers.[21][7]Working groups are expected to monitor publications and review knowledge regularly, with updates proposed every three to five years according to emerging evidence.[20]

Follow-up is multidisciplinary and alternates between oncologists, the treating physician and gynaecologists.[13][14]It includes clinical review four months after treatment, six-monthly review for five years and annual review thereafter, alongside mammography and ultrasound surveillance, symptom-directed investigation, cardiac monitoring after anthracyclines or trastuzumab, and gynaecological surveillance for patients receiving tamoxifen.[14][25][26]Working-group meetings were publicly funded, but no overall budget, treatment costs, resource allocation or financing strategy is specified.[20]

Monitoring & Evaluation

The protocol establishes an evidence-informed quality and accountability process for breast-cancer care, combining periodic scientific review, graded recommendations, external validation, clinical surveillance and multidisciplinary decision-making.[16][20][13][14]

• Monitor scientific publications and convene working groups regularly to review new knowledge; propose protocol updates every three to five years, subject to the availability of new evidence, under oversight from the relevant scientific society’s protocol-monitoring committee.[20]
• Assess the methodological quality of reviewed studies, assign levels of scientific evidence and grade recommendations accordingly; where evidence is insufficient, permit recommendations based on strong professional consensus.[16]
• Validate protocol quality through external review of content, format, readability and applicability, followed by review by the Moroccan Society of Medical Sciences Coordination Committee, the National Health Insurance Agency’s Medical Technical Committee and ministerial approval.[20]
• Require working-group members to submit declarations of honour or declarations of interests, where applicable, to support transparency in protocol development.[19][16]
• Record Breast Imaging Reporting and Data System (BI-RADS) classifications and diagnostic hypotheses in mammography, ultrasound and magnetic resonance imaging reports; use two radiologists reading screening examinations at different times.[3][4][21]
• Standardise pathological reporting by documenting malignancy, prognostic and anatomical factors, tumour and nodal characteristics, excision status, receptor status and post-treatment residual disease where relevant.[6][7]
• Use defined surveillance intervals for imaging abnormalities, including follow-up of BI-RADS 3 microcalcifications at six months and BI-RADS 3 opacities at four months, while requiring histological verification for BI-RADS 4 or 5 lesions.[5]
• Verify radiotherapy simulation using portal imaging or gammagraphy and provide weekly medical monitoring during radiotherapy.[10][27]
• Evaluate response to neoadjuvant chemotherapy regularly, use multidisciplinary consultation to address non-response or progression, and determine whether surgery becomes feasible.[22]
• Conduct post-treatment clinical examination at four months, every six months for five years and annually thereafter; supplement clinical surveillance with mammography and ultrasound, with the first mammogram six months after treatment completion.[14][25][26]
• Monitor cardiac safety by measuring left-ventricular ejection fraction every three months during anthracycline or trastuzumab treatment, then at six months, one year and annually for four years after treatment.[14]
• Provide annual gynaecological clinical surveillance for patients receiving tamoxifen, with additional annual vaginal ultrasound for pre-menopausal women who do not have ovarian suppression.[14]
• Investigate suspected recurrence through symptom-directed examinations and, where mammography or ultrasound findings are uncertain, breast magnetic resonance imaging.[14]

The source does not set out a unified programme-level indicator set, routine reporting timetable, cancer registry or surveillance architecture, audit cycle, implementation performance targets, or formal accountability framework beyond the protocol-development and clinical quality mechanisms described.[17][1][9][23]

Costing & Financing

Financing information is very limited. Working-group meetings for protocol development were organised and financed from public funds, but no monetary amount, budget period or named public funding stream is provided.[20]

• Identify public funding as the source supporting working-group meetings involved in protocol development.[20]
• Recognise that the protocol implies substantial service inputs, including multidisciplinary personnel, imaging, pathology, surgery, systemic therapies, radiotherapy equipment, follow-up investigations and rehabilitation support, but it does not attach costs or financing arrangements to these inputs.[9][10][11][15]
• Note radiotherapy resource requirements, including a linear accelerator or cobalt unit, computed-tomography simulation for dosimetry, verification imaging or gammagraphy, and brachytherapy or electron capability where indicated.[10]
• Note that treatment resources listed include anticancer medicines, endocrine therapies, trastuzumab, breast prostheses and catheter chambers, without allocations, procurement arrangements or unit prices.[28][18]

No overall budget, expenditure estimate, unit cost, patient cost, resource-allocation formula, funding gap, resource-mobilisation target, donor contribution, cost-effectiveness analysis or economic assumption is specified.[20][27][13][25]